Summary The expression of thymidine kinase -an enzyme of the DNA precursor pathway -is strictly regulated during the normal cellular cycle, but is much higher and permanently expressed in malignant growing cells. We used this fact to detect neoplastic cells in samples freshly taken from leukaemia patients and kept frozen in liquid nitrogen until analysis. Using a new cytofluorometric assay for thymidine kinase in single cells, we were able to identify leukaemic cells in a surplus of normal ones. Our results demonstrate the benefits of this assay for leukaemia diagnosis.
Thymidine kinase (TK) catalyses the ATP-dependent phosphorylation of thymidine and deoxyuridine. The activity of TK is strictly regulated during the normal cell cycle, peaking at the onset of DNA synthesis but remaining extremely low in resting cells (Bello, 1974; Wawra et al., 1981) . In the past, we have established a cytofluorometric method based on the uptake of a fluorescent nucleoside that is subsequently phosphorylated by the cells in the same manner as thymidine (Hengstschlager and Wawra, 1993a) . The intracellular accumulation of this fluorescence, when determined by a flow cytometer, is an indication of the TK activity per every single cell.
We have already shown that normal cells express their TK gene during a limited period in early S-phase, whereas in abnormally growing cells continuous transcription causes a much higher steady-state concentration of TK mRNA and therefore a much higher activity of the enzyme (Hengstschlager et al., 1994a) . When applied to cells in culture, our new cytofluorometric assay allows us to discriminate between normal growing cells, like diploid fibroblasts, and virally transformed cells or lines derived from tumours (Hengstschlager et al., 1994b) . Moreover, this method enabled us to identify a few transformed cells mixed with a 10 000-fold excess of normal ones (Hengstschlager and Wawra, 1993b ethanol) at 37°C and 7.5% carbon dioxide. After harvesting by centrifugation for 5 min at 1000 r.p.m., cells were washed twice with PBS. The cells were resuspended in 100 mM Tris HCl (pH 7.4), 154 mM sodium chloride, 1 mM calcium chloride, 0.5 mm magnesium chloride, 0.1% NP-40 and 0.2% bovine serum albumin (BSA) (a 10 x stock solution of BSA was stored at -20°C and was thawed briefly before analysis) to a concentration of about 1 x 106 cells ml -'. DNA staining was performed with 1.5 pg ml-' ethidium bromide for 10-20 min on ice. Cells were analysed within the following 20 min to ensure that they were still alive and that the phosphorylated thymidine analogue was not washed out.
The fluorescences reflecting TK activity and DNA content were simultaneously measured with a Partec PAS-I1 flow cytometer. Excitation was UV light (< 380 nm) for both dyes; filters were set to obtain a complete separation of emission of the fluorescent analogue (500 nm) and of ethidium bromide (605 nm).
Results
In order to show how our results have to be interpreted, the result of a typical analysis (bone marrow) is shown in Figure 1 . Figure 2) . Malignant growing cells always exhibit more TK activity than S-phases of normal cells do. These cells are therefore found in another area of the diagram (Figure 1) . So, in cases where we find a separated population of cells with high TK content, we can identify these as malignant cells.
This was found in the samples 2-4, 6-9 and 12 -14 (Table I and Figure 2 ), although in sample number 12 it was not that obvious. In the two remaining samples, 1 and 11 (and also in 12), the areas of normal and neoplastic cells overlap, although the area representing malignant cells is densely populated (compare with control samples 5, 10 and 15). Such samples are also strongly positive, but for a safe diagnosis a reference sample (like 5) should have been run simultaneously to ensure that no type of artefact causes the high TK values.
In an earlier report, we analysed artificial mixtures of growing normal and malignant cells and were able to identify tumour cells mixed with a 10 000-fold excess of normal ones (Hengstschlager and Wawra, 1993b) . From the data in the present study, we may conclude that a total of at least some 50 or 100 malignant cells are necessary for identification under average conditions. Therefore, the ratio of normal vs neoplastic cells is not critical: 104-106 cells can easily be analysed in a normal sample so that the limit of, say, 100 malignant cells may be reached even when these cells are extremely sparse.
It is important to emphasise that intracellular TK activity is not a diagnostic marker for the forms of leukaemia listed in Table I , but is a general indicator for malignant growth.
Discussion
One of the major demands in tumour biology is a cheap and robust diagnostic tool for the detection of tumour cells (Hall et al., 1994) . We expect our method to provide such a tool as it is easy to use and applicable to hospitals and clinics without sophisticated molecular biology laboratories. In our Table 1 for the identification of samples.
previous publications, we have demonstrated the application of this assay on a wide variety of transformed or tumourderived cell lines. However, it may always be argued that, during the artificial passages in culture, the cells accumulate modifications and artefacts that do not mirror the native situation. Here we present the first in vivo studies, showing that this method is very effective for biopsy material.
The method seems useful for discrimination between leukaemic and normal cells to get a first, fast diagnosis. Clearly, additional morphological, cytogenetic and perhaps molecular genetic studies are necessary to define subtypes in regard to diagnosis and therapeutic procedures. Further, our new test is most promising for the detection of residual malignant cells after leukaemia chemotherapy. The morphological methods that are presently used fail to detect fewer than 1% blasts in peripheral blood, and complete remission is assumed if fewer than 5% of blasts are found in bone marrow. There have been many attempts to reduce these levels by cytogenetic techniques, by in situ hybridisation, by polymerase chain reactions, etc. but all these techniques raise serious disadvantages (see Campana and Pui, 1995 for a review). Methods using molecular biology are extremely sensitive, but are specific for a certain type of leukaemia or even for a certain patient, whereas our test is obviously universally applicable. With this method, we can find a few malignant cells in relatively large populations (up to a total of 106 cells) so that we can detect minimal residual disease levels of 1 in 10 000. If done with fresh material, the whole procedure from the first addition of the dye until the final diagnosis, might be performed within 3 h, even if a few different samples are prepared simultaneously. In this context, we want to emphasise that this method should work with all types of flow cytometric instruments provided that the excitation is done with UV light (300-350 nm). Any UV lamp or UV laser will be sufficient, but not the most common argon ion laser (488 nm excitation).
In the case of morphological screening of bone marrow, a few malignant cells may be hidden by the amount of normal precursor cells that are always present. We have every reason to believe that we see only the malignant blasts in the fluorescence pattern. Recently we found that in a tumour progression model, only the later and malignant stages were positive in our assay, whereas the first biopsy containing benign tumour cells looked normal (Hengstschlager et al., 1996) .
But why is TK content an indicator of malignancy in so many different types of leukaemia? Elevated levels of thymidine kinase were found many times in serum from patients with malignant diseases. Enzymes involved in purine metabolism show normal or reduced activity in tumours when compared with normal cells, but thymidylate synthase, connected with the de novo pathway of deoxynucleotides, was found to increase with tumour progression (Bardot et al., 1994) . We have shown already that thymidine kinase also increases with tumour progression (Hengstschlager et al., 1996) and that the change in regulation of TK activity during the cell cycle is accompanied by a similar change in TK mRNA steady-state levels (Hengstschlager et al., 1994a) . Obviously, activity of TK is dominated by the amount of its mRNA, and the difference between normal and malignant cells is at the level of transcription or shortly thereafter. But the TK gene is one of a family of S-phase-regulated genes which share common properties in respect to their promoters. DNA polymerase a, dihydrofolate reductase and thymidylate synthase are other members and all are regulated by the transcription factor E2F, which itself is regulated by the retinoblastoma gene product (pRb) (Nevins, 1992) . This pRb is a target for the tumour antigens of DNA tumour viruses (Ogris et al., 1993; Mudrak et al., 1994) , so that in virustransformed cells, pRb allows E2F to activate these genes. Recently, we have shown that the mRNA levels of both subunits of ribonucleotide reductase and of dihydrofolate reductase, but not of deoxycytidine kinase, mirror exactly the regulation of TK mRNA during the cell cycle of normal and transformed cells (Hengstschlager et al., 1994c) .
But pRb is cell cycle-regulated by the cyclin system [see Sieff (1994) for a review], and this is known to be a target for two of the most prominent tumour suppressor gene products, p16 and p53 (Peters, 1994) . p16 is an inhibitor of the cyclin D/cdk4 kinase (Serrano et al., 1993) , p53 is an activator of p21 which inhibits cyclin D/cdk2 and cyclin E/cdk2 (Waga et al., 1994) . Therefore, the described loss of enzymatic regulation is an indicator for many different tumour-causing mechanisms: presence of viral coded tumour antigen (Hengstschlager et al., 1994a) Compared with other S-phase-regulated genes, TK appears to be the most convenient indicator for this effect: the half-life of the enzyme is short enough to reflect variations during the cell cycle; there is no further regulation on protein level; and TK activity is easy to detect on a cellular level with our new assay. Our results demonstrate that samples from patients are as suitable for this identification as cultivated cells. This opens the possibility of using this method widely for a preliminary clinical diagnosis and especially for detection of minimal residual disease during leukaemia therapy.
